OncoTAb

OncoTAb is a private, pre-revenue biotech company leveraging its patented tMUC1-targeting antibody platform to address unmet needs in oncology. Its initial focus is the commercial launch of the Agkura Personal Score, a blood-based diagnostic test for breast cancer detection in women with dense breasts, which represents a significant market opportunity. Beyond diagnostics, the company has a preclinical pipeline exploring the same targeting agent for therapeutic applications, including radioimmunotherapy and CAR-T cell therapies for breast and pancreatic cancers.

Proprietary platform based on a fully humanized monoclonal antibody (hTAB004) that specifically targets the tumor-associated form of the MUC1 protein (tMUC1). This platform is applied across multiple modalities: diagnostic immunoassays, radioimmunoconjugates for imaging/therapy (theranostics), and engineered T-cell therapies (CAR-T, bispecific antibodies).

In diagnostics, OncoTAb competes with other liquid biopsy companies (e.g., Grail, Freenome) and imaging adjuncts like ultrasound and MRI for dense breast screening. Its tMUC1 focus is a key differentiator. Therapeutically, it would enter a competitive but rapidly evolving field of targeted radiopharmaceuticals and solid-tumor CAR-T therapies, where its unique antigen target may provide a niche advantage if clinical efficacy is proven.